Terms and Conditions

BY USING THIS SITE YOU ACKNOWLEDGE THAT GENENTECH, INC. AND NOVARTIS PHARMACEUTICALS CORPORATION ARE PROVIDING THE MATERIAL FOR INFORMATIONAL PURPOSES ONLY AND THAT GENENTECH, INC. AND NOVARTIS PHARMACEUTICALS CORPORATION AND THEIR AGENTS, AFFILIATES, PARTNERS OR LICENSORS ARE NOT PROVIDING THE MATERIALS TO YOU FOR THE PURPOSES OF GIVING YOU MEDICAL ADVICE. YOU SHOULD NOT RELY ON THE MATERIALS IN DECIDING ON A TREATMENT PLAN, DRUG USAGE OR ANY OTHER MEDICAL ADVICE REGARDING THE MATERIALS, AND GENENTECH, INC. AND NOVARTIS PHARMACEUTICALS CORPORATION AND THEIR LICENSORS STRONGLY URGE THAT PATIENTS CONSULT WITH A PHYSICIAN IN CONNECTION WITH ANY AND ALL TREATMENT OPTIONS THAT MAY BE AVAILABLE.

BY USING THIS WEBSITE, YOU ACCEPT THE INFORMATION, PRODUCTS AND SERVICES PROVIDED HEREIN AS IS. NEITHER GENENTECH, INC. NOR NOVARTIS PHARMACEUTICALS CORPORATION MAKE ANY EXPRESS OR IMPLIED WARRANTY REGARDING THE ACCURACY, CONTENT, COMPLETENESS, RELIABILITY, OPERABILITY OR LEGALITY OF INFORMATION CONTAINED WITHIN THIS WEBSITE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF PROPRIETARY RIGHTS.

IN NO EVENT SHALL GENENTECH, INC., OR NOVARTIS PHARMACEUTICALS CORPORATION OR THEIR AGENTS, AFFILIATES, PARTNERS OR LICENSORS BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS RELATED TO THE USE OF OUR WEBSITES, WHETHER IN AN ACTION OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, OR OTHER TORTIOUS ACTION ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE MATERIALS CONTAINED ON THIS SITE.

XOLAIR (Omalizumab) for Subcutaneous Use Indication

XOLAIR is indicated for adults and adolescents (12 years of age and older) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with ICS. XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients. Safety and efficacy have not been established in other allergic conditions.

WARNING

Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, patients should be closely observed for an appropriate period of time after XOLAIR administration, and health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Patients should also be informed of the signs and symptoms of anaphylaxis and instructed to seek immediate medical care should symptoms occur (see WARNINGS, and PRECAUTIONS, Information for Patients).

XOLAIR Safety Information

  • XOLAIR should only be administered in a health care setting by health care providers prepared to manage anaphylaxis that can be life- threatening.
  • XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR (see Boxed WARNING). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction.
  • Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR- treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders.
  • Patients should be given and instructed to read the Medication Guide before starting treatment and before each subsequent treatment.
  • Patients receiving XOLAIR should be told not to decrease the dose of, or stop taking any other asthma medications unless otherwise instructed by their physician.
  • The adverse reactions most commonly observed among patients treated with XOLAIR in clinical studies included injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.